Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism

[1]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[2]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[3]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[4]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[5]  D. Lewis,et al.  A MOLECULAR MODEL OF CYP2D6 CONSTRUCTED BY HOMOLOGY WITH THE CYP2C5 CRYSTALLOGRAPHIC TEMPLATE: INVESTIGATION OF ENZYME-SUBSTRATE INTERACTIONS , 2003, Drug metabolism and drug interactions.

[6]  James R. Halpert,et al.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. V. Shaw,et al.  Structural and Mechanistic Studies of Galactoside Acetyltransferase, the Escherichia coli LacA Gene Product (*) , 1995, The Journal of Biological Chemistry.

[8]  M. Meyer,et al.  The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers , 2009, Drug Metabolism and Disposition.

[9]  S. Ekins,et al.  (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[10]  M. Odomi,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[11]  F Peter Guengerich,et al.  Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. , 2003, Biochemistry.

[12]  G. Tucker,et al.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. , 1996, The Biochemical journal.

[13]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[14]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[15]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[16]  A. Somogyi,et al.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. , 1994, British journal of clinical pharmacology.

[17]  L. Bertilsson,et al.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. , 1999, British journal of clinical pharmacology.

[18]  G. Tucker,et al.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. , 2001, The Biochemical journal.

[19]  G. Baker,et al.  Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[21]  Gordon C K Roberts,et al.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. , 2004, The Biochemical journal.

[22]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[23]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[24]  David C. Richardson,et al.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..

[25]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[26]  Nico P E Vermeulen,et al.  Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.

[27]  S. Narimatsu,et al.  Change in enantioselectivity in bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. , 2005, Chirality.

[28]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[29]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[30]  L. Bertilsson,et al.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.

[31]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[32]  D. L. Wilson,et al.  Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  W. König,et al.  Determination of the enantiomeric composition of mexiletine and its four hydroxylated metabolites in urine by enantioselective capillary gas chromatography. , 1996, Chirality.

[34]  Jozef Hritz,et al.  Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking. , 2008, Journal of medicinal chemistry.

[35]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[36]  Chris Oostenbrink,et al.  Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. , 2007, Current drug metabolism.

[37]  M. Lennard.  Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. , 1990, Pharmacology & toxicology.

[38]  G. Tucker,et al.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  P. Ortiz de Montellano,et al.  Revisiting the mechanism of P450 enzymes with the radical clocks norcarane and spiro[2,5]octane. , 2002, Journal of the American Chemical Society.

[40]  Gordon C K Roberts,et al.  Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6* , 2003, The Journal of Biological Chemistry.

[41]  H. Kalant,et al.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  Stewart B Kirton,et al.  Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6 , 2002, Proteins.

[43]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[44]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[45]  C David Stout,et al.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.

[46]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[47]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[48]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[49]  Woody Sherman,et al.  Improving database enrichment through ensemble docking , 2008, J. Comput. Aided Mol. Des..

[50]  Bernard Faller,et al.  Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. , 2009, Journal of medicinal chemistry.

[51]  S. Imaoka,et al.  Isoform-selective metabolism of mianserin by cytochrome P-450 2D. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[52]  B. Singh,et al.  Investigations of the mode of action of a new antidysrhythmic drug, Kö 1173 , 1972, British journal of pharmacology.

[53]  Serge Léger,et al.  Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. , 2002, Biochemistry.

[54]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[55]  N. Vermeulen,et al.  Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. , 2004, Biochemical pharmacology.

[56]  L. Bertilsson,et al.  1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[57]  Andrej ⩽ali,et al.  Comparative protein modeling by satisfaction of spatial restraints , 1995 .

[58]  C David Stout,et al.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.

[59]  Thomas A. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996, J. Comput. Chem..

[60]  A. Lindgren,et al.  Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[61]  G. D. Johnston,et al.  Peripheral vascular effects of bufuralol in hypertensive and normal subjects: A comparison with propranolol and pindolol , 2004, European Journal of Clinical Pharmacology.

[62]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[63]  W. Abraham.  Beta-blockers: the new standard of therapy for mild heart failure. , 2000, Archives of internal medicine.

[64]  T. Imai,et al.  In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[65]  J. Kastrup,et al.  MEXILETINE FOR TREATMENT OF CHRONIC PAINFUL DIABETIC NEUROPATHY , 1988, The Lancet.

[66]  A. Yu,et al.  Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[67]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[68]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[69]  M. Sutcliffe,et al.  Why Is Quinidine an Inhibitor of Cytochrome P450 2D6? , 2005, Journal of Biological Chemistry.

[70]  Chris Oostenbrink,et al.  Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. , 2006, Journal of medicinal chemistry.

[71]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[72]  J. Turgeon,et al.  Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. , 2003, Pharmacogenetics.

[73]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[74]  Michael J. E. Sternberg,et al.  Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.